Skip to main content

Doubled Your Impact for Our Ocean

Did you know that because of this caring community, more than 27,000 marine mammals have been rescued since the Center opened in 1975?

The animals are showing us that human activity is putting their lives at risk and threatening the health of our ocean. That’s why studying ocean health is key to helping marine mammals. And you can make a real difference today by doubling your impact for our ocean.

You can celebrate 27,000 animals rescued with your gift of just $27. Your life-saving donation will be matched dollar-for-dollar by a group of generous donors like you!

Double my impact today
California sea lion
harbor seal

Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion and Pacific harbor seal

Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion (Zalophus californianus) and Pacific harbor seal (Phoca vitulina richardii)
  • Medicine

Abstract

Pharmacokinetics studies have investigated meloxicam, a non-steroidal antiinflammatory drug, dosing strategies in a wide variety of non-domestic animals; however, there is no prior study examining well-founded dosing for pinnipeds. To develop dosing protocols, pharmacokinetic information is needed, with an examination of differences between pinniped species. Apparently, healthy California sea lions (Zalophus californianus: CSL; n= 13) and Pacific harbor seals (Phoca vitulina richardii: PHS; n= 17) that had completed rehabilitation were enrolled into a population-based pharmacokinetic study. Each animal was administered a single oral dose of meloxicam at 0.1 mg/ kg, and two blood samples were collected from each animal at varying intervals during a 96-h study period. Plasma concentrations of meloxicam were determined by high-pressure liquid chromatography. Data were analyzed with nonlinear mixed effects modeling (Phoenix® NLME™, Certara, St. Louis, MO 63105, USA). The results indicated that in PHS, peak plasma concentration (Cmax) was 0.33 μg/mL with an elimination half-life (Ke t½) of 31.53 h. In CSL, Cmax was 0.17 μg/mL with Ke t½ of 32.71 h. All animals enrolled completed the study without outward adverse clinical signs. The elimination half-life was longer than previously recommended dosing intervals for pinnipeds; however, we cannot speculate in the optimum clinical dose from these results.


Trumbull, E.J., Papich, M.G., Peters, M., Whitmer, E.R., Rivard, M. and Field, C.L., 2024. Comparative pharmacokinetics of a single oral dose of meloxicam in the California sea lion (Zalophus californianus) and Pacific harbor seal (Phoca vitulina richardii). Journal of Veterinary Pharmacology and Therapeutics, 47(6), pp.485-491.

medicine
Cara Field
Emily Whitmer
medicine, pharmacokinetics, California sea lion, Pacific harbor seal, dosing, meloxicam

Meet The Experts

Related Publications

Related News